アルツハイマー病の治療に伴う抗神経炎症活性を持つ高度に選択的なBChE阻害剤の発見
Yarong Zhao1, Kun Wu1, Wei Luo1
1School of Pharmaceutical Science, School of Basic Medicine, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China.
European journal of medicinal chemistry
|August 30, 2025
まとめ
新しい化合物であるN14は,神経保護と認知の利点を提供するブチリルコリネステラーゼ (BChE) の強力で選択的な阻害を示しています. このBChE阻害剤は,アルツハイマー病 (AD) の多機能治療薬として有望であることを示しています.
科学分野:
- 神経科学
- 薬剤化学
- 薬理学について
背景:
- ブチリルコリネステラス (BChE) は,進行アルツハイマー病 (AD) の治療標的である.
- 既存のBChE阻害剤は効力や選択性が欠けている可能性があります.
- N-ベンゾイルトリプタミンは 抗神経炎症性があります
研究 の 目的:
- 強力で選択的なBChE阻害剤として,カルバマート基のN-ベンゾイルトリプタミン誘導体を設計し,合成する.
- これらの誘導体の有効性を臨床前モデルで評価する.
- アルツハイマー病の治療のための 鉛化合物を特定するために
主な方法:
- 20種類のカルバマート基の新種のN-ベンゾイルトリプタミンの合成
- BChEとヒトのBChE (hBChE) の抑制活性と選択性を決定するインビトロ酵素測定.
- ニューロプロテクションとアグリゲーション阻害のためのAβ ((1-42) モデルを用いたin vitroアッセイ.
- 認知障害,コレリン系の調節,薬理動力学,BBBの透過性を評価するためにマウスでのin vivo研究.
主要な成果:
- 化合物N14はBChE阻害において高い効能と選択性を示した (eqBChE IC50 = 18. 00 ± 0. 485 pM,SI = 84, 7252).
- リバスティグミンと比較して,N14はAβ1-42誘発の損傷に対する優れた神経保護効果を示し,Aβ1-42の自己集積を抑制しました.
- N14はスコポラミン誘発の認知障害を有意に改善し,海馬におけるBChEとアセチルコリンレベルを改善した.
- N14は前述のBChE阻害剤よりも好ましい安全性プロファイル,良好な薬理動力学,BBB浸透性,半減期の3倍を示した.
結論:
- 新型BChE阻害剤N14は,アルツハイマー病に対する強力で,選択的で,多機能の鉛化合物です.
- コリン機能障害を修正するN14の有効性は,リバスティグミンよりも高い.
- N14の好ましいin vivo特性は,ADの治療薬としての可能性を示唆しています.
関連する概念動画
Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
206
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
206
Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
siRNA - Small Interfering RNAs
17.0K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
17.0K
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
825
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
825


